On November 9, 2021 NeoTX Therapeutics, Ltd. (NeoTX), a clinical-stage immuno-oncology company, reported a presentation on the company’s lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C (Press release, NeoTX, NOV 9, 2021, View Source [SID1234594928]). The poster presentation will highlight preclinical data demonstrating that NAP enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentation are as follows:

Title: Tumor Targeted Superantigen (TTS), Naptumomab Estafenatox (NAP), enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors
Abstract Number: 576 (ePoster)
Lead Author: Yael Sagi, Ph.D.
Category: Combination Immunotherapies
Date & Time: The ePoster will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.